在肾移植中麦考酚酸酯药物浓度监测研究现状
被引量：5
摘要
麦考酚酸酯是一种抗嘌呤代谢的免疫抑制剂,近年来已广泛应用于防治各类实体器官移植术后的排斥反应,效果确切。但在药物临床使用过程中出现了个体差异和各种不良事件,因此有必要进行药物浓度监测。本文对麦考酚酸酯的疗效及不良反应、药代动力学特点、监测麦考酚酸酯药代动力学的意义、方法及指标选择等作一综述。
出处
《世界临床药物》
CAS
2006年第2期80-85,共6页
World Clinical Drug
二级参考文献15
-
1[1]Allison AC, Eugui EM. Pruine metabolism and immunosuppressive effects of mycophenolate mofetil(MMF). Clin Transpl,1996,10(Part2):77
-
2[2]Sollinger HW, Cho S, Danovitch G, et al. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients, the US Renal Transplant Mycophenolate Mofetil Study Group. Tranlplantation,1995,60:225
-
3[3]Keown P, Harry P, Mathew T, et al. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation,1996,61:1029
-
4[4]Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid: a consensus panel report. Clin Biochem,1998,31:317
-
5[5]Sollinger HW, U.S Renal Transplant Study Group. Mycophenolate mofetil for prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation,1995,15;60:225
-
6[6]Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacolkinet,1998,34:429
-
7[7]Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil(RS61443): a short review. Transplant Proc,1996,28:925
-
8[8]Nicholls AJ. Opportunities for therapeutic monitoring of mycophnolate mofrtil dose in renal transplantation suggested by the pharmacokinetic/ pharmacodynamic relationship for mycophenolate acid and suppression of rejection. Clin Biochem,1998,31:329
-
9[9]Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem,2001,34:17
-
10[10]Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem,2001,34:77
共引文献9
-
1张明,焦正,钟建泳,郁韵秋,陆福明.肾移植患者中麦考酚酸及其葡萄糖苷酸代谢物的稳态药动学[J].复旦学报（医学版）,2006,33(4):491-493.
-
2文吉秋,黎磊石,陈劲松,唐政,孙启全,张明超,刘志红.他克莫司与环孢素A对肾移植患者霉酚酸酯血药浓度影响的比较[J].肾脏病与透析肾移植杂志,2006,15(6):515-519. 被引量：10
-
3孟凡航,王长希,陈立中,任斌,费继光,黎曙霞,邱江,邓素雄,李军.肾移植术后不同时间麦考酚酸暴露量的变化——附16例报告[J].新医学,2007,38(3):158-160. 被引量：3
-
4孟凡航,王长希,陈立中,任斌,黎曙霞,费继光,邓素雄,邱江,李军,陈国栋.老年肾移植患者霉酚酸的药物代谢动力学特征及其临床意义[J].肾脏病与透析肾移植杂志,2007,16(5):421-425. 被引量：2
-
5占锦峰,胡伟新.霉酚酸酯血药浓度监测的临床应用[J].肾脏病与透析肾移植杂志,2007,16(5):468-472. 被引量：7
-
6袁学露,李水军,沈兵,张渊,余琛,刘皋林.液相色谱-串联质谱法测定肾移植患者的麦考酚酸血浆浓度及其药动学研究[J].医药导报,2009,28(4):447-449.
-
7任斌,李敏薇,李碧虹,许琼,吴爱琴,何秋毅,陈孝.霉酚酸酯在肾移植受者的多剂量药代动力学研究[J].今日药学,2009,19(5):20-22. 被引量：2
-
8马一平.实体器官移植患者霉酚酸的药动学特征及其影响因素[J].天津药学,2011,23(3):52-55. 被引量：5
-
9方丽纳,张博,平丽英,张薇,周屹峰,柳志强.霉酚酸酯的临床应用进展[J].发酵科技通讯,2021,50(1):14-19. 被引量：4
同被引文献37
-
1沈杰,焦正,郁韵秋,迟丹怡,张明,钟明康.高效液相色谱荧光检测法测定人血浆中麦考酚酸的浓度[J].中国新药与临床杂志,2005,24(1):11-13. 被引量：13
-
2Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients [ J ]. Clin Pharmacokinet, 2007,46 (1) :13.
-
3Bopp R J, Schirmer RE, Meyers DB. Determination of mycophenolic acid and its glucuronide metabolite in plasma[J]. J Pharm Sci,1972,61 (11) :1750.
-
4Suntornsuk L,Meyer T. A micellar electrokinetic capillary chromatography method for monitoring mycophenolic acid in serum of transplant recipients [ J ]. Pharmazie,2005,60 (2) :115.
-
5Irtan S,Azougagh S,Monchaud C,et al. Comparison of high- performance liquid chromatography and enzyme-multiplied immunoassay techniqueto monitor mycophenolic acid in paediatric renal recipients [ J 1. Pediatr Nephrol, 2008,23 : 1859.
-
6Staatz CE, Tett SE. Clinical pharmacokinetics andpharmacodynamics of mycophenolate in solid organ transplantrecipients[J]. Clin Pharmacokinet, 2007, 46(1): 13-58.
-
7van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomizeddouble-blind, multicenter plasma concentration controlled studyof the safety and efficacy of oral mycophenolate mofetil for theprevention of acute rejection after kidney transplantation[J].Transplantation, 1999, 68(2): 261-266.
-
8Barten MJ, Rahmel A, Garbade J, et al. C0h/C2h monitoring of thepharmacodynamics of cyclosporine plus mycophenolate mofetilin human heart transplant recipients[J]. Transplant Proc, 2005,37(2):1360-1361.
-
9Suntornsuk L, Meyer T, Lindgren A, et al. A micellar electrokineticcapillary chromatography method for monitoring mycophenolicacid in serum of transplant recipients[J]. Pharmazie, 2005, 60(2):115-119.
-
10Filler G, Lepage N. To what extent dose the understandingof pharmacokinetics of mycophenolate mofetil influence itsprescription[J]. Pediatr Nephrol, 2004, 19(9): 962-965.
引证文献5
-
1段京莉,王筱楠.新型免疫抑制剂麦考酚酸酯的临床应用及治疗药物监测[J].中国执业药师,2008,5(11):10-13.
-
2赵冠人,申健,冯端浩.高效液相色谱法测定人血浆中麦考酚酸的浓度[J].中国医院用药评价与分析,2012,12(3):230-233.
-
3彭明丽,赵冠人,申健.肾移植患者吗替麦考酚酯血药浓度监测[J].中国药物应用与监测,2014,11(1):5-8. 被引量：3
-
4曾毅刚,邱建新.固相检测法在肾移植术后抗体监测中的应用[J].世界临床药物,2014,35(6):351-357.
-
5孙蔚倩,施丹晔,胡屏,佟怡婧,唐余燕,吴佳君,贺海东,徐旭东.吗替麦考酚酯致移植肾失功的血液透析患者难治性贫血1例及文献复习[J].重庆医学,2022,51(16):2817-2820.
二级引证文献3
-
1刘可欣,徐珽,蒋学华.肾移植患者吗替麦考酚酯药时曲线下面积与不良反应的相关性[J].中国医院药学杂志,2016,36(8):658-661. 被引量：3
-
2徐怡.吗替麦考酚酯的药代动力学及其临床应用研究进展[J].北方药学,2017,14(2):133-134. 被引量：2
-
3田中华,杨雅淋,李艳艳,李剑芳.吗替麦考酚酯致粒细胞缺乏1例并文献复习[J].中国药物应用与监测,2022,19(3):200-203.
-
1邹霞.别嘌醇对慢性心力衰竭的治疗效应和作用机制[J].中国药房,2010,21(26):2476-2478.
-
2曝光[J].药品评价,2013,10(21):7-7.
-
3警惕别嘌醇片引起的重症药疹[J].中国社区医师,2013(43):18-19.
-
4卢纹凯.降尿酸药物且用且谨慎[J].江苏卫生保健（今日保健）,2015(8):35-35. 被引量：1
-
5周炎仪,郭丽兰,黄蔚绮,林小凤.抗痛风药的合理应用[J].临床合理用药杂志,2012,5(6):36-36.
-
6王宇真,范葓.抗痛风药的合理使用[J].中国执业药师,2007(3):30-31. 被引量：2
-
7王金玲,阎雪莹,李春燕.二氢杨梅素胃内漂浮片处方研究[J].中国现代应用药学,2014,31(2):182-186. 被引量：6
-
8黄燕飞,刘志红,黄海东,黎磊石.霉酚酸酯对血管内皮细胞白细胞介素-6产生的影响[J].肾脏病与透析肾移植杂志,2003,12(1):15-18. 被引量：2
-
9布立影.“三防”配合降尿酸[J].现代养生,2005(9):20-20.
-
10王莉,周红,张三奇,顾宜,方坤泉,周敏,奚苗苗,连佳芳.白黎芦醇脂质体的制备工艺改进[J].第四军医大学学报,2005,26(20):1902-1904. 被引量：6
